In summary, the CORIN study aligns with the results of the ADAURA trial, providing further evidence of the efficacy and tolerability of adjuvant EGFR-TKI as a postoperative treatment for patients with stage IB NSCLC with EGFR mutations. Here, EGFR is linked to non-small cell lung carcinoma.